PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position Paper - The AAPS Journal
| SpringerLink |
remove preview |
|
| PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position Paper - The AAPS Journal |
| Interest and efforts to use recombinant adeno-associated viruses (AAV) as gene therapy delivery tools to treat disease have grown exponentially. However, gaps in understanding of the pharmacokinetics/pharmacodynamics (PK/PD) and disposition of this modality exist. This position paper comes from the Novel Modalities Working Group (WG), part of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ). |
| View this on SpringerLink > |
|
|
------------------------------
Pankajini Mallick PhD
Principal Scientist, Preclinical Pharmacokinetics | DMPK
San Diego CA
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------